News & Updates
Filter by Specialty:
Dimethyl fumarate bests interferon β-1a in paediatric-onset multiple sclerosis
The use of dimethyl fumarate (DMF) in the treatment of children with paediatric-onset multiple sclerosis (POMS) appears to produce more favourable effects than interferon β-1a (IFNβ-1a), with those on DMF being less likely to have new or newly enlarging lesions and experience relapse, according to data from the open-label CONNECT study.
Dimethyl fumarate bests interferon β-1a in paediatric-onset multiple sclerosis
10 Oct 2022
Bronchodilators ineffective in symptomatic, tobacco-exposed patients without COPD
Bronchodilators, used in the treatment of chronic obstructive pulmonary disease (COPD), did not appear to benefit individuals with a history of smoking and respiratory symptoms who did not have airflow obstruction, results of the US-based RETHINC* study showed.
Bronchodilators ineffective in symptomatic, tobacco-exposed patients without COPD
08 Oct 2022
Sugemalimab for stage III NSCLC: Efficacy, safety signals sustained in final PFS analysis
In the final progression-free survival (PFS) analysis of the GEMSTONE-301 study, sugemalimab demonstrated sustained efficacy and safety as consolidation treatment for individuals with unresectable stage III non-small cell lung cancer (NSCLC) whose disease had not progressed following either concurrent chemoradiotherapy (cCRT) or sequential CRT (sCRT).
Sugemalimab for stage III NSCLC: Efficacy, safety signals sustained in final PFS analysis
07 Oct 2022
Dapagliflozin prevents worsening heart failure, CV death
Dapagliflozin is a safe treatment to reduce the risk of worsening heart failure (HF) or cardiovascular death both in patients with and without history of recent HF hospitalization, a study has shown.
